The company announced a final dividend of Rs 5.50 per equity share and has fixed July 7, 2025 as the record date for the purpose of dividend.
The company’s revenue from operations were up 8% at Rs 12,959 crore over Rs 11,983 crore reported in the corresponding quarter of the last financial year.
The profit after tax (PAT) was down 26% over Rs 2,913 crore reported by the company in Q3FY25 while the topline was also 5% lower on a sequential basis versus 13,675 crore reported in the October-December quarter of FY25.
For the full financial year net profit stood at Rs 10,965 crore versus Rs 9,610 crore crore in Q4FY24. Meanwhile, the revenue expanded by 8.5% to Rs 52,578 crore in Q4FY25 versus Rs 48,497 crore in the quarter ago.
The company reported exceptional items worth Rs 678 crore along with exceptional tax expense of Rs 377 crore for year ended March 31 , 2025. This includes a charge of $37.44 million (Rs 316 crore) including legal expenses of $0.7 million ( Rs 5.82 crore) in quarter ended December 31, 2024 on agreement of a settlement in principle on the primary financial terms, with no admission of wrongdoing in the US.The company reported expenses of Rs 9,956 crore in the quarter under review, which was 10,349 crore in Q3FY25 and Rs 9,672 crore in the year ago period. The expenses were incurred under the heads like cost of materials consumed, purchases of stock-in-trade, employee benefit expenses and finance cost.
The earnings were announced after market hours and shares of Sun Pharma ended at Rs 1,724.70 on the NSE, down by Rs 7.10 or 0.41%.